RuthAnn Gordon, Mary Kate Kasler, Kristen Stasi, Yelena Shames, Mimma Errante, Kathryn Ciccolini, Anna Skripnik Lucas, Pam Raasch, Erica Fischer-Cartlidge
BACKGROUND: Immunotherapy, specifically the use of checkpoint inhibitors, offers patients with cancer an alternative to chemotherapy, targeting different pathways to destroy cancer cells. The side effects of immunotherapies, as well as their impact on normal tissue, need to be assessed and managed based on their mechanisms of action. OBJECTIVES: This article presents an overview of immune-related adverse events (AEs).
. METHODS: Common immune-related toxicities, as well as rare and refractory toxicities, are reviewed...
April 1, 2017: Clinical Journal of Oncology Nursing